In parallel, exoASO-STAT6, another candidate from Codiak’s exoASOTM platform, targets STAT6 in tumor-associated macrophages (TAMs), particularly within hepatic tumors such as hepatocellular carcinoma (HCC). Here, STAT6 is linked to neoplasm.